Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany

Background: Adjuvant treatment options have become the standard therapy for stage III and IV resectable cutaneous melanoma. Two recent studies led to the registration of dabrafenib and trametinib as targeted therapies for BRAF-mutated melanoma, and of immunotherapy with nivolumab irrespective of BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Wahler, S, Müller, A, Koll, C, Seyed-Abbaszadeh, P, Von Der Schulenburg, JM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781974/
https://www.ncbi.nlm.nih.gov/pubmed/33456727
http://dx.doi.org/10.1080/20016689.2020.1861804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781974/
https://www.ncbi.nlm.nih.gov/pubmed/33456727
http://dx.doi.org/10.1080/20016689.2020.1861804

Ejemplares similares